Equities analysts expect that Hologic, Inc. (NASDAQ:HOLX) will post sales of $792.51 million for the current quarter, according to Zacks. Seven analysts have issued estimates for Hologic’s earnings, with the highest sales estimate coming in at $795.80 million and the lowest estimate coming in at $789.50 million. Hologic posted sales of $726.80 million in the same quarter last year, which suggests a positive year-over-year growth rate of 9%. The firm is scheduled to announce its next quarterly earnings report after the market closes on Wednesday, November 8th.
On average, analysts expect that Hologic will report full year sales of $792.51 million for the current year, with estimates ranging from $3.04 billion to $3.05 billion. For the next year, analysts anticipate that the business will post sales of $3.29 billion per share, with estimates ranging from $3.23 billion to $3.41 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Hologic.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The business had revenue of $806.10 million for the quarter, compared to analyst estimates of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company’s revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.51 EPS.
HOLX has been the topic of several research analyst reports. Royal Bank Of Canada lowered their target price on Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 3rd. BidaskClub cut Hologic from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Barclays PLC reduced their price target on Hologic from $53.00 to $51.00 and set an “overweight” rating for the company in a report on Thursday, August 3rd. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Hologic in a report on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $47.77.
In other news, Director Lawrence M. Levy sold 9,596 shares of the business’s stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total transaction of $353,228.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Elaine Ullian sold 6,902 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $40.12, for a total value of $276,908.24. Following the sale, the director now owns 23,810 shares in the company, valued at $955,257.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,775 shares of company stock valued at $1,175,662. Corporate insiders own 0.79% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in HOLX. Capital World Investors bought a new stake in shares of Hologic during the second quarter valued at approximately $312,441,000. HealthCor Management L.P. bought a new stake in shares of Hologic during the second quarter valued at approximately $76,604,000. Columbus Circle Investors bought a new stake in shares of Hologic during the second quarter valued at approximately $54,511,000. Vanguard Group Inc. increased its position in shares of Hologic by 4.2% during the second quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock valued at $1,340,850,000 after purchasing an additional 1,200,825 shares during the period. Finally, Koch Industries Inc. increased its position in shares of Hologic by 15,554.1% during the second quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock valued at $1,125,000 after purchasing an additional 1,142,138 shares during the period. Institutional investors and hedge funds own 95.68% of the company’s stock.
Shares of Hologic (NASDAQ HOLX) traded down 0.08% on Friday, hitting $37.21. 2,666,134 shares of the stock traded hands. The company’s 50 day moving average is $37.23 and its 200 day moving average is $41.44. Hologic has a one year low of $35.15 and a one year high of $46.80. The stock has a market cap of $10.44 billion, a price-to-earnings ratio of 13.86 and a beta of 0.91.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Hologic Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hologic Inc. and related companies.